ARCA biopharma (ARCA biopharma) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Dividend Payout Ratio?

ARCA biopharma's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for ARCA biopharma's Dividend Payout Ratio or its related term are showing as below:

ABIO's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.455
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-15), the Dividend Yield % of ARCA biopharma is 0.00%.

ARCA biopharma's Dividends per Share for the months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

ARCA biopharma Dividend Payout Ratio Historical Data

The historical data trend for ARCA biopharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Dividend Payout Ratio Chart

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

ARCA biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ARCA biopharma's Dividend Payout Ratio

For the Biotechnology subindustry, ARCA biopharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARCA biopharma's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Dividend Payout Ratio falls into.

ARCA biopharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

ARCA biopharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.37
	=	N/A

ARCA biopharma's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.14
	=	N/A

ARCA biopharma (NAS:ABIO) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

ARCA biopharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma (ARCA biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

HQ10:Germany

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

http://www.arcabiopharma.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Executives

James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp	10 percent owner, other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp	other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver	other: See Remarks	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff	officer: S.V.P., General Counsel	8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker	officer: Chief Financial Officer	10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer	officer: Chief Operating Officer	C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby	officer: VP, Finance	11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell	10 percent owner
David M Mott	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett	10 percent owner
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202